<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01390064</url>
  </required_header>
  <id_info>
    <org_study_id>110396</org_study_id>
    <nct_id>NCT01390064</nct_id>
  </id_info>
  <brief_title>Vaccination of High Risk Breast Cancer Patients</brief_title>
  <official_title>Phase 1 Safety Study of a Carbohydrate Mimotope Based Vaccine With MONTANIDE ISA 51 VG Adjuvant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective - Determine the safety and tolerability of a peptide mimotope-based vaccine upon
      immunization of breast cancer subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After signing Institutional Review Board (IRB) approved consent, cohorts of 3-6 stage IV
      breast cancer subjects will be enrolled into the study. The vaccine doses will be prepared
      and dispensed by the University of Arkansas for Medical Sciences (UAMS) Pharmacy following
      the manufacturer's instructions. Subjects will receive 1.0 mL subcutaneous (SC) injections of
      the vaccine on 5 separate occasions during Weeks 1, 2, 3, 7, and 19. The first cohort will
      begin with the 300 mg dose, and then the subsequent cohorts will escalate to 500 mg or
      de-escalate to 100 mg as determined by the toxicity criteria. The immunization at week 19 is
      considered a booster immunization. The vaccine will be administered at rotating sites on the
      limbs or abdomen. The study will last for approximately 12 - 24 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2011</start_date>
  <completion_date type="Actual">July 2019</completion_date>
  <primary_completion_date type="Actual">July 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Dose-limiting Toxicity (Defined as an Adverse Event of Grade 3 or Higher)</measure>
    <time_frame>9 weeks per subject</time_frame>
    <description>The safety and tolerability of the P10s-PADRE/MONTANIDE ISA51 VG vaccine will be determined by toxicity assessments throughout the duration of the study. Subjects will be evaluated for toxicity using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Stage IV Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Initial Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Escalation Cohort</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 500 micrograms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>De-escalation Cohort</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 100 micrograms</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG</intervention_name>
    <description>All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule</description>
    <arm_group_label>De-escalation Cohort</arm_group_label>
    <arm_group_label>Escalation Cohort</arm_group_label>
    <arm_group_label>Initial Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subjects of all races with histologically or cytologically confirmed stage IV
             breast cancer are eligible. The cancer may be newly diagnosed metastatic or relapsed
             after primary or adjunctive therapy and must not have required a treatment change for
             2 months. Treatments with anti-estrogen therapy or chemotherapy are allowed. The
             chemotherapy regimen cannot contain steroids in the pre or post supportive care
             medications. If a subject is on an investigational drug, the drug must be cleared from
             the body over a period of 4 weeks.

          -  Disease staging will be done according to the American Joint Commission on Cancer
             (AJCC), sixth edition.

          -  Age 18 years and older of all races and ethnicity.

          -  ECOG Performance Status 0 or 1.

          -  Subjects must not have an active infection requiring treatment with antibiotics.

          -  Subjects must not have other significant medical, surgical or psychiatric conditions,
             or require any medication or treatment, which may interfere with compliance of the
             treatment regimen.

          -  Subjects must not have a diagnosis or evidence of organic brain syndrome, significant
             impairment of basal cognitive function or any psychiatric disorder that might preclude
             participation in the full protocol.

          -  Subjects must have no other current malignancies. Subjects with prior history at any
             time of any in situ cancer, including lobular carcinoma of the breast in situ,
             cervical cancer in situ, atypical melanocytic hyperplasia or Clark I melanoma in situ
             or basal or squamous skin cancer are eligible, provided they are disease-free at the
             time of registration. Subjects with other malignancies are eligible if they have been
             continuously disease free for ≥ 5 years prior to the time of registration.

          -  Subjects must not have autoimmune disorders or conditions of immunosuppression. This
             includes, but is not limited to being treated with corticosteroids, including oral
             steroids (i.e. prednisone, dexamethasone), continuous use of topical steroid creams or
             ointments or any steroid-containing inhalers. Subjects who have been on systemic
             steroids will require a 6-week washout period. Subjects who discontinue the use of
             these classes of medication for at least 6 weeks prior to registration are eligible
             if, in the judgment of the treating physician, the subject is not likely to require
             these classes of drugs during the treatment period. Replacement doses of steroids for
             subjects with adrenal insufficiency are allowed.

          -  Women of childbearing potential must not be pregnant (negative serum pregnancy test
             must be done 48 hours prior to receiving the first dose of study drug) or
             breastfeeding,due to the unknown effects of peptide/mimotope vaccines on a fetus or
             infant.

          -  Women of childbearing potential must be counseled to use an accepted and effective
             method of contraception (including abstinence) while on treatment and for a period of
             18 months after completing or discontinuing treatment. Accepted methods include oral
             contraceptives, barrier method, Intrauterine Devices (IUDs), and abstinence.

          -  Subjects must have obtained a white blood cell (WBC) count ≥ 3,000/mm3 and platelet
             count ≥ 100,000/mm3 within 2 weeks prior to registration.

          -  Subjects must have a serum glutamic-oxaloacetic transaminase (SGOT)/aspartate
             aminotransferase test (AST) and bilirubin ≤ 2 x institutional upper limit (IUL) of
             normal and serum creatinine ≤ 1.8 mg/dl, all obtained within 2 weeks prior to
             registration.

          -  Subjects must be immunocompetent as measured by responsiveness to two recall antigens
             by skin testing.

          -  All subjects who wish to participate in the study must sign an informed consent
             approved by the UAMS Institutional Review Board (IRB).

          -  Laboratory tests must be completed within 2 weeks before the first dose.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Hutchins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 29, 2011</study_first_submitted>
  <study_first_submitted_qc>July 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2011</study_first_posted>
  <results_first_submitted>July 26, 2018</results_first_submitted>
  <results_first_submitted_qc>February 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 3, 2019</results_first_posted>
  <last_update_submitted>August 7, 2019</last_update_submitted>
  <last_update_submitted_qc>August 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 1, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT01390064/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Initial Cohort</title>
          <description>Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms
Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule</description>
        </group>
        <group group_id="P2">
          <title>Escalation Cohort</title>
          <description>Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 500 micrograms
Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Initial Cohort</title>
          <description>Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms
Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule</description>
        </group>
        <group group_id="B2">
          <title>Escalation Cohort</title>
          <description>Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 500 micrograms
Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.0" spread="17.4"/>
                    <measurement group_id="B2" value="56.0" spread="9.5"/>
                    <measurement group_id="B3" value="56.5" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Performance Status (ECOG)</title>
          <units>ECOG units on a scale 0 Best-5 Worst</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.0" spread="0.0"/>
                    <measurement group_id="B2" value="0.3" spread="0.6"/>
                    <measurement group_id="B3" value="0.2" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lines of Prior Endocrine Therapy</title>
          <units>Numbers of therapy</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.7" spread="1.2"/>
                    <measurement group_id="B2" value="1.7" spread="1.5"/>
                    <measurement group_id="B3" value="1.2" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lines of Prior Chemotherapy</title>
          <units>Numbers of therapy</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.3" spread="0.6"/>
                    <measurement group_id="B2" value="1.3" spread="0.6"/>
                    <measurement group_id="B3" value="1.3" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Dose-limiting Toxicity (Defined as an Adverse Event of Grade 3 or Higher)</title>
        <description>The safety and tolerability of the P10s-PADRE/MONTANIDE ISA51 VG vaccine will be determined by toxicity assessments throughout the duration of the study. Subjects will be evaluated for toxicity using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.</description>
        <time_frame>9 weeks per subject</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Initial Cohort</title>
            <description>Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms
Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule</description>
          </group>
          <group group_id="O2">
            <title>Escalation Cohort</title>
            <description>Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 500 micrograms
Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Dose-limiting Toxicity (Defined as an Adverse Event of Grade 3 or Higher)</title>
          <description>The safety and tolerability of the P10s-PADRE/MONTANIDE ISA51 VG vaccine will be determined by toxicity assessments throughout the duration of the study. Subjects will be evaluated for toxicity using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 months during and after the vaccine was administered.</time_frame>
      <desc>All-cause Mortality AEs and Serious Adverse Events were monitored but there are none to report.
All Other(Not Including Serious) Adverse Events have been provided in a table format.</desc>
      <group_list>
        <group group_id="E1">
          <title>Initial Cohort</title>
          <description>Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms
Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule</description>
        </group>
        <group group_id="E2">
          <title>Escalation Cohort</title>
          <description>Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 500 micrograms
Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <description>Grade 1 - Unanticipated - Not related to the study - Not related to the study therapy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <description>Grade 1 - Unanticipated - Not related to the study - Not related to the study therapy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colonic hemorrhage</sub_title>
                <description>Grade 2- Unanticipated - Not related to the study - Not related to the study therapy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other: tender knots at the site of injections</sub_title>
                <description>Grade 2 - Anticipated - Definitely related to the study - Definitely related to the study therapy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune disorder: Increase in ANA</sub_title>
                <description>Grade 1 - Anticipated - Possibly related to study - definitely related to study therapy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <description>Grade 2 - Unanticipated - Not related to the study - Not related to the study therapy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <description>Grade 1 - Unanticipated - Not related to the study - Not related to the study therapy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <description>Grade 1 - Unanticipated - Not related to the study - Not related to the study therapy</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>Grade 1 - Unanticipated - Definitely related to they study - Possibly related to study therapy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <description>Grade 2 - Unanticipated - Not related to the study - Not related to the study therapy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>Grade 2 - Unanticipated - Not related to the study - Not related to the study therapy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <description>Grade 1 - Unanticipated - Unlikely related to the study - Unlikely related to study therapy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <description>Grade 1 - Unanticipated - Not related to they study - Not related to the study therapy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus disorder</sub_title>
                <description>Grade 1 - Unanticipated - Not related to the study - Not related to the study therapy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <description>Grade 1 - Unanticipated - Not related to the study - Not related to the study therapy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>Grade 1 - Unanticipated - Not related to the study - Not related to the study therapy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Other: Subcutaneous nodule at injection site</sub_title>
                <description>Grade 1 - Anticipated - Definitely related to the study - Definitely related to the study Therapy</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Rash maculopapular</sub_title>
                <description>Grade 1 - Unanticipated - Definitely related to they study - Definitely related to study therapy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Skin induration: small lumps on abdomen at site of study drug administration</sub_title>
                <description>Grade 1 - Anticipated - Definitely related to the study - Not related to study therapy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <description>Grade 2 - Anticipated - Not related to the study - Not related to the study therapy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <description>Grade 2 - Unanticipated - Not related to the study - Not related to the study therapy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Skin Induration</sub_title>
                <description>Grade 1 - Unanticipated - Possibly related to they study - Definitely related to the study therapy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Skin induration: abdomen and right upper arm</sub_title>
                <description>Grade 2 - Anticipated - Possibly related to the study - Definitely related to the study therapy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pain of skin: constant soreness at injection sites when the area is touched</sub_title>
                <description>Grade 2 - Anticipated - Possibly related to the study - Possibly related to the study therapy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <description>Grade 1 - Anticipated - Possibly related to the study - Possibly related to the study therapy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Other: bitten by unknown insect on the back of left leg</sub_title>
                <description>Grade 2 - Unanticipated - Not related to the study - Not related to the study therapy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Laura Hutchins</name_or_title>
      <organization>University of Arkansas for Medical Sciences</organization>
      <phone>5016868274</phone>
      <email>hutchinslauraf@uams.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

